
What if a single blood test could transform every stage of cancer care?
In this essential episode of Labcorp Perspectives Oncology, Dr. Rebecca Previs welcomes Dr. Anne-Renee Hartman, a pioneering oncologist and diagnostics leader, to share the latest breakthroughs in tissue-free, methylation-based MRD testing.
Explore how these blood-based assays are shaping decision-making across early detection, recurrence monitoring, and real-time treatment response—delivering value at every point in the cancer journey. Discover data, real-world implications, and why these tools could soon become a mainstay in oncology care.
Don’t miss this eye-opening conversation—tune in now.
Follow Us
- LinkedIn @labcorp
- X @labcorp
- Facebook @labcorp
- Instagram @labcorp
- YouTube @LabcorpVideo
Presented by Labcorp Oncology
https://www.labcorp.com/oncology
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More episodes from "Labcorp Perspectives: Oncology"



Don't miss an episode of “Labcorp Perspectives: Oncology” and subscribe to it in the GetPodcast app.








